Abstract 354P
Background
In Malaysia, up to 68% of cancer patients uses CAM, with CAM disclosure at only 7.6%. Perception of doctors’ poor knowledge on CAM, and non-belief in its practice are some reasons cited for non-disclosure. This may lead to various complications.
Methods
This cross-sectional study was carried out in 2 university hospitals in Malaysia from 1st July to 23rd December 2016. All doctors and nurses of Oncology Departments were included. Subjects were briefed on the study before questionnaires were distributed and returned anonymously once completed. The questionnaire was adopted with local adaptations, from a study done in Japan on perceptions and attitudes on CAM. A pilot study was done and the final validated version consists of 2 sections. Section A consists of questions on socio-demographic characteristics of respondent. Section B consisted of questions to assess the respondent’s knowledge, perception and attitude on CAM. Each question was given a point scale. Based on total points obtained, respondents were classified into good or poor knowledge, positive or negative perception and attitude towards CAM.
Results
Total of 60 nurses and 26 doctors responded, with 16 male and 70 female. Generally, all respondents have poor knowledge on CAM. Two thirds (67.4%) were not aware of the existence of the National Policy on CAM in Malaysia. Most have very little or no knowledge on the CAM modalities listed. The respondents have negative perception on CAM, with 83.7% feel the lack of evidence in its effectiveness. Most (72%) think that there is a definite or possible interaction between CAM products and anticancer drugs. All have negative attitude on CAM except 8.1% of respondents encouraging the use of CAM. Majority do not encourage the use of CAM products in both early (79.1%) and advanced (64%) stage.
Conclusions
Oncology-related healthcare providers have poor knowledge, with negative perception and attitude towards CAM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
403P - Clinical profile, practice pattern and outcomes in ALK-positive lung cancer: Real-world data from India
Presenter: Akhil Kapoor
Session: e-Poster Display Session
404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?
Presenter: Jia-Hui Weng
Session: e-Poster Display Session
405P - Promising efficacy as combination therapy of DFP-14323, protease inhibitor, with EGFR-TKI in patients with metastatic NSCLC harboring EGFR mutation
Presenter: Hiroshige Yoshioka
Session: e-Poster Display Session
406P - Anti-PD-1 versus anti-PD-L1 inhibitors in first-line therapy non-small-cell lung cancer: A systematic review and meta-analysis
Presenter: Angelo Brito
Session: e-Poster Display Session
407P - Integrating histologic and genomic characteristics to predict tumour mutation burden of early-stage non-small cell lung cancer
Presenter: Yuan Qiu
Session: e-Poster Display Session
408P - Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Presenter: Julia Maevskaya
Session: e-Poster Display Session
409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer
Presenter: Haifeng Qin
Session: e-Poster Display Session
410P - Frequency and spectrum of primary resistance mechanism in Chinese ALK+ non-small cell lung cancer patients progressing on crizotinib: A multicenter study
Presenter: Wen-xian Wang
Session: e-Poster Display Session
411P - Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation
Presenter: Yoshihiko Taniguchi
Session: e-Poster Display Session
412P - Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial
Presenter: Andrea Camerini
Session: e-Poster Display Session